CA2084514A1 - O-glycosylated ifn-alpha - Google Patents

O-glycosylated ifn-alpha

Info

Publication number
CA2084514A1
CA2084514A1 CA002084514A CA2084514A CA2084514A1 CA 2084514 A1 CA2084514 A1 CA 2084514A1 CA 002084514 A CA002084514 A CA 002084514A CA 2084514 A CA2084514 A CA 2084514A CA 2084514 A1 CA2084514 A1 CA 2084514A1
Authority
CA
Canada
Prior art keywords
ifn
alpha
peak
pad
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002084514A
Other languages
English (en)
French (fr)
Inventor
Guenther Adolf
Adolf Himmler
Horst Johann Ahorn
Inge Kalsner
Ingrid Maurer-Fogy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19904021917 external-priority patent/DE4021917A1/de
Priority claimed from DE19904035877 external-priority patent/DE4035877A1/de
Application filed by Individual filed Critical Individual
Publication of CA2084514A1 publication Critical patent/CA2084514A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002084514A 1990-07-10 1991-07-06 O-glycosylated ifn-alpha Abandoned CA2084514A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19904021917 DE4021917A1 (de) 1990-07-10 1990-07-10 Glykosyliertes ifnalpha
DEP4021917.8 1990-07-10
DEP4035877.1 1990-11-12
DE19904035877 DE4035877A1 (de) 1990-11-12 1990-11-12 O-glycosyliertes ifn-alfa2

Publications (1)

Publication Number Publication Date
CA2084514A1 true CA2084514A1 (en) 1992-01-11

Family

ID=25894855

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002084514A Abandoned CA2084514A1 (en) 1990-07-10 1991-07-06 O-glycosylated ifn-alpha

Country Status (16)

Country Link
EP (1) EP0538300B1 (enExample)
JP (1) JPH06502987A (enExample)
KR (1) KR930701601A (enExample)
AT (1) ATE104348T1 (enExample)
AU (1) AU650893B2 (enExample)
CA (1) CA2084514A1 (enExample)
CZ (1) CZ386392A3 (enExample)
DE (1) DE59101397D1 (enExample)
DK (1) DK0538300T3 (enExample)
ES (1) ES2063515T3 (enExample)
FI (1) FI930058A7 (enExample)
HU (1) HUT65846A (enExample)
NO (1) NO930059L (enExample)
PL (1) PL297610A1 (enExample)
SK (1) SK386392A3 (enExample)
WO (1) WO1992001055A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5541071A (en) * 1992-02-07 1996-07-30 New England Medical Center Hospitals, Inc. Assay for identifying antagonists of gastrin and CCK-B receptors
NZ245771A (en) * 1992-02-07 1994-08-26 New England Medical Center Inc Mammalian gastrin/cholecystokinin b (cck-b) receptor and antagonists
EP0626448A3 (de) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
AU713611B2 (en) 1994-10-28 1999-12-09 Delft Diagnostic Laboratory B.V. New polynucleic acid sequences for use in the detection and differentiation of prokaryotic organisms
AU3980497A (en) * 1996-08-14 1998-03-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vector for polynucleotide vaccines
GB9904695D0 (en) * 1999-03-01 1999-04-21 Imp Cancer Res Tech Peptide
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
ES2561985T3 (es) * 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CN102212019B (zh) 2003-03-14 2015-05-27 蔚所番有限公司 支化水溶性聚合物及其缀合物
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
JP5743368B2 (ja) 2004-01-08 2015-07-01 ラショファーム ゲーエムベーハー ペプチドのo結合型グリコシル化
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
AR078117A1 (es) 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー/エス ポリペプチドコンジュゲートの精製方法
RS52845B (sr) 2007-04-03 2013-12-31 Biogenerix Ag Postupci tretmana korišćenjem glikopegiliranog g-csf
JP5876649B2 (ja) 2007-06-12 2016-03-02 ラツィオファルム ゲーエムベーハーratiopharm GmbH ヌクレオチド糖の改良製造法
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
WO2014102101A1 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
WO2014102103A2 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Heterologous intron within a signal peptide
RU2610173C1 (ru) * 2016-03-30 2017-02-08 Илья Александрович Марков Рекомбинантная плазмида pFM-IFN-17, обеспечивающая экспрессию интерферона альфа-2b человека, рекомбинантная плазмида pFM-АР, обеспечивающая экспрессию фермента метионинаминопептидазы E. coli, биплазмидный штамм Escherichia coli FM-IFN-АР (pFM-IFN-17, pFM-АР) - продуцент (Met-) рекомбинантного интерферона альфа-2b человека

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN150740B (enExample) * 1978-11-24 1982-12-04 Hoffmann La Roche
JPS58501543A (ja) * 1981-08-14 1983-09-16 エイ/エス アルフレツド ベンツオン ヒトインタ−フエロン蛋白とヒトインタ−フエロン蛋白に対する抗体に関する改良
DE3306060A1 (de) * 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps

Also Published As

Publication number Publication date
AU8208291A (en) 1992-02-04
PL297610A1 (enExample) 1992-07-13
SK386392A3 (en) 1994-08-10
FI930058L (fi) 1993-01-08
EP0538300A1 (de) 1993-04-28
HU9300036D0 (en) 1993-04-28
DE59101397D1 (de) 1994-05-19
ES2063515T3 (es) 1995-01-01
NO930059D0 (no) 1993-01-08
KR930701601A (ko) 1993-06-12
AU650893B2 (en) 1994-07-07
FI930058A0 (fi) 1993-01-08
EP0538300B1 (de) 1994-04-13
HUT65846A (en) 1994-07-28
CZ386392A3 (en) 1993-08-11
ATE104348T1 (de) 1994-04-15
FI930058A7 (fi) 1993-01-08
WO1992001055A1 (de) 1992-01-23
DK0538300T3 (da) 1994-10-10
NO930059L (no) 1993-01-08
JPH06502987A (ja) 1994-04-07

Similar Documents

Publication Publication Date Title
AU650893B2 (en) O-glycosylated alpha-2 interferon
US4966849A (en) CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
KR100361997B1 (ko) 안정한살균/투과성-증가단백질산물및그것을포함하는제약학적조성물
EP0668351B1 (en) Erythropoietin analogs
AU646014B2 (en) Novel platelet-derived growth factor B chain analogs and method for homogeneous production thereof
KR960009054B1 (ko) 사람 유래의 당단백질 및 그 당단백질로서 되는 생리활성인자와 이를 활성 성분으로 하는 제제
EP0412557B1 (en) Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
IL166543A (en) Il-7 drug substance, il-7 comprising composition, their preparation and uses thereof
IE61773B1 (en) Novel lymphokine related peptides
EP1535929A2 (en) Megakaryocyte stimulating factors
JPH07138292A (ja) マウス白血病抑制因子
CA2134030C (en) Soluble interferon .alpha.-receptor, its preparation and use
CA2209298C (en) Mpl ligand analogs
AU651083B2 (en) Production of biologically active platelet-derived growth factor from high expression host cell systems
WO1993000357A1 (en) Therapeutic polypeptides based on von willebrand factor
CA1340689C (en) Human b-cell differentiation factor and process of producing said factor
KR100237582B1 (ko) Tpo 활성을 갖는 단백질의 제조방법
IL81879A (en) Purification of minactivin for homogeneity, production of minactivin as recombinant techniques, and uses of homogeneous or recombinant minactivin
EP0508417B1 (en) Monoclonal antibody, polypeptides and production thereof
FI104424B (fi) Menetelmä onkostatiini M -mutantin valmistamiseksi
WO1991000907A1 (en) Monocyte chemotactic proteins and related peptides
WO1992006999A1 (en) Therapeutic fragments of von willebrand factor
JP3292873B2 (ja) 組換肝実質細胞増殖因子
JP2816971B2 (ja) 組換肝実質細胞増殖因子
IE68876B1 (en) Thrombin-binding substance and process for preparing the same

Legal Events

Date Code Title Description
FZDE Discontinued